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Introduction
In treating patients with severe sepsis, physicians are mainly
concerned with biologic, physiologic, and clinical outcomes.
Of those patients who survive to hospital discharge, little is
known regarding their physical functioning (ability to conduct
activities of daily life such as walking around), psychologic
functioning (mental well-being), and social functioning (com-
munication and relationships with others) after sepsis.
Because ‘quality of life’ (QoL) describes or characterizes what
the patient has experienced as a result of sepsis care, it is a
useful and important supplement to traditional physiologic or
biologic measures of health status; that is, assessments of
effectiveness need to include wider measures of benefits to
patients, and particularly those that measure the impact from
the patient’s point of view. A relevant therapeutic benefit may
also be in restoring the patient’s ability to function on a daily
basis, to socialize, and to be alert. In fact, a long-term focus on
AT = antithrombin; QoL = quality of life; SAPS = Simplified Acute Physiology Score.
Abstract
Introduction Treatment of sepsis is aimed at increasing both the duration and quality of survival. A
long-term focus on quality of life (QoL) in clinical trial evaluations of sepsis care should be a priority.
Method QoL data were used to evaluate the effects of intravenous antithrombin III treatment for
severe sepsis measured for up to 90 days during the follow-up phase of the KyberSept phase III
clinical trial. A visual analog scale and a Karnofsky scale were used to measure physical, psychologic,
and social QoL at regular intervals. Changes from baseline between placebo and antithrombin III
groups were assessed using Wilcoxon statistical tests, with additional analyses by severity of illness
and admitting diagnosis.
Results Among all sepsis survivors in the trial, there was a significant advantage on some attributes of
QoL in the antithrombin III subgroup of patients who did not receive heparin as compared with the
corresponding placebo group.
Discussion The present study represents the first attempt to evaluate patient QoL over a relatively
long period in a large, randomized, placebo-controlled sepsis trial. Over a 90-day period, survivors of
severe sepsis receiving antithrombin III experienced significant improvements as compared with
placebo on several attributes of QoL. In conclusion, the present study demonstrated that clinical
improvements over an extended time period with antithrombin III were complemented by improvements
in QoL, particularly in social and psychologic functioning, in many patients.
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QoL in clinical trial evaluations was among the recommenda-
tions of a recent sepsis international advisory group [1].
This report presents the results of an evaluation of QoL among
sepsis survivors, done as part of the phase III multicenter
KyberSept trial. To the best of our knowledge, limited informa-
tion on the effects of sepsis treatment on QoL has been
reported [2,3]. The report focuses on the effects of antithrom-
bin (AT) III therapy related to physical, mental, and social func-
tioning of patients who were randomly assigned to either
high-dose intravenous treatment with Kybernin P® (Aventis
Behring, Marburg, Germany; a plasma-derived AT III concen-
trate, 30,000 IU over 4 days) or placebo during up to 90 days
of follow up. In the trial, overall survival tended to favor AT III
over placebo after 90 days of follow up, although the differ-
ences were nominal. However, the AT III group that did not
receive concomitant heparin exhibited a nominally statistically
significant survival advantage over placebo at 90 days of
follow-up. The purpose of this investigation was to establish
whether these trends also held for the subjective effects of AT
III in severe sepsis. It concludes that AT III treatment is effective
in improving long-term patient QoL, and that future outcome
research studies of severe sepsis should follow up patients
throughout their hospital stay and after discharge.
Method
Quality of life instruments
There are a number of important conceptual and methodologic
issues in assessing QoL in people who are critically ill, not least
of which is the question of how it should be defined. Recent
attempts to define QoL have resulted in the development of a
functional definition that is measurable, evaluable over time,
and readily applied to patients over a wide range of illness
severity. Most attempts incorporate the domains of physical,
psychologic/cognitive, and social functioning. Each of these
domains can be measured in two dimensions: objective
assessments of functioning or health status; and more subjec-
tive perceptions of general health. The patient’s subjective
experience translates that objective assessment into the actual
QoL experienced. Thus, where the term ‘QoL’ is used in the
present study, it refers to a composite of objective functional
impairment and subjective perceptions and expectations. The
instruments chosen for the study were designed to reflect this.
QoL gives information on what medical care has achieved for
the patient, but severe sepsis is a difficult area in which to
obtain such information. Normally, QoL data should be
obtained directly from the patient. Unfortunately, patients hos-
pitalized with severe sepsis may be unable to complete a
QoL measure or it may be too burdensome. Rather than lose
information on patients, the physician investigator was used
as a proxy respondent.
Two instruments were used to cover the objective and sub-
jective dimensions. The objective component in the study
was measured using the Karnofsky performance scale. The
Karnofsky scale emphasizes physical performance and
dependency; it is a descriptive, ordinal scale that ranges from
100 (good health) to 0 (dead). Trial investigators assigned
percentages based on physical performance (Table 1). The
Karnofsky scale is designed to assess independent function-
ing and appears to have substantial validity as an indicator of
overall physical status. The validity and reliability of the scale
have been shown in several populations [4–6].
The subjective component of the trial was measured with
multiple items using a visual analog scale [7]. A visual analog
scale is a line with defined end-points on which investigators
indicate a patient’s health state. Thus, the investigator placed
a mark along a 100 mm line that best described his or her
assessment of the patient with the domain in question. There
were six domains (Table 2). The scales ranged from 0 (worst
health status) to 100 (best health status). The visual analog
scale has been used in several studies of QoL [8–10]. Relia-
bility estimates for visual analog scaling items range from
0.40 to 0.95 [11], and these estimates compare favorably
with those for other scales [12,13].
The six domains of the first visual analog scale and the
Karnofsky score are hereafter referred to as ‘attributes’.
The clinical trial
The KyberSept trial was a large, international, phase III clinical
trial that enrolled 2314 patients who were evaluable for efficacy
Table 1
Karnofsky performance scale: objective assessment of
physical performance and dependency
Investigator 
assigned 
percentage Features
100% Normal; no complaints and no evidence of disease
90% Able to carry on normal activities; minor signs or 
symptoms of disease
80% Normal activities but with effort; some signs or 
symptoms of disease
70% Cares for self, but is unable to carry on normal 
activities or to do active work
60% Requires occasional assistance, but is able to care for 
most needs
50% Requires considerable assistance and frequent 
medical care
40% Disabled; requires special care and assistance
30% Severely disabled; hospitalization is indicated but 
death is not imminent
20% Hospitalization necessary, very sick, active supportive 
treatment necessary
10% Moribund; fatal processes progressing rapidlyand safety in a randomized, double-blind, placebo-controlled
design in order to determine the role of high-dose AT III in
patients with severe sepsis. Patients randomly assigned to the
AT III group received a total of 30,000 IU plasma-derived AT III
(Kybernin P®) administered as a loading dose of 6000 IU given
over 30 min, followed by a continuous infusion of 6000 IU/day
for 4 days. The study protocol permitted investigators to pre-
scribe unfractionated or low-molecular-weight heparin for
venous thrombosis prophylaxis (≤10,000 IU/day subcuta-
neous) and heparin flushes for vascular catheter potency
(≤2 IU/kg body weight per hour intravenous).
In the trial, the all-cause mortality rate at 28 days was almost
identical between the placebo group and the group that
received AT III (38.7% versus 39.9%; not significant). At the
90-day time point, the AT III group had a nominally lower mor-
tality than did the placebo group (46.4% versus 48.5%).
Among the 680 patients in the trial who did not receive
heparin concomitantly, there was a statistically significant dif-
ference between the AT III and placebo groups. In this sub-
group, mortality at 90 days in the AT III subgroup was 44.9%,
versus 52.5% in the placebo subgroup (Pnominal = 0.03). A
complete description of that study and results are reported
elsewhere [14].
Outcomes
The Karnofsky scale and visual analog scales were both
administered by physician investigators when patients enrolled
in the trial (referred to as ‘baseline’); during the trial at 28 days,
56 days and 90 days after enrollment; and at discharge from
the hospital (if it occurred other than at one of those three
intervals). For example, if a patient survived and was dis-
charged at day 60, there would be four assessments (i.e.
baseline and days 28, 56, and 60). The primary outcome was
change in attribute scores until 90 days after patients were
assigned to either treatment or placebo. For this analysis, two
patient populations were used. The smaller population was the
group remaining in the hospital 90 days from baseline – the
‘in-hospital survivors’. The larger population comprised all sur-
vivors at 90 days, or at the time point closest to 90 days. This
group is labeled the ‘all-survivors’ group. It includes the in-hos-
pital group. In cases in which there was no patient response at
90 days because they had been discharged, the data from the
last assessment but before 90 days were used. This method is
equivalent to using the last observation carried forward.
The last observation carried forward method uses the last
observed value for that case, and it therefore assumes that
the outcome remains constant at the last observed value after
discharge. Otherwise stated, it is assumed that QoL in sepsis
patients is stable on average for the short time period
between discharge and 90 days. It is not possible to con-
clude firmly that the change in QoL between discharge and
90 days was small and unbiased. However, the fact that the
hospital discharge curve between AT III and placebo was
almost identical provides evidence that the comparison
between treatment groups should be unbiased. Moreover,
the physician investigator, the patient, and the family were
blinded to the treatment assignment (placebo versus AT III)
throughout the duration of the clinical trial.
The secondary outcome was change in the attribute scores
at 28, 56, and 90 days after assignment to treatment or
placebo. That outcome measure was used in order to
compare relative changes between AT III and placebo groups
at the 28-day, 56-day, and 90-day assessments.
Analysis
Patient characteristics
Mean, standard deviation, and range values (for age) and per-
centages for relevant patient characteristics (at enrollment
and administration of heparin) are reported. The overall trial
population is presented, as well as the all-survivors and the
in-hospital survivors groups. The other variables used were
Simplified Acute Physiology Score (SAPS) II [15] (a measure
of severity of illness), admitting diagnosis, and concomitant
use of heparin. In the SAPS II system, a score-to-risk transfor-
mation developed by Le Gall et al. [16] for sepsis patients
was used. The risk intervals were identical to the SAPS II
strata defined in the trial.
Changes in quality of life between baseline and 90 days
For both the in-hospital survivors and the all-survivors groups,
mean changes and standard deviations between baseline
and 90 days are shown. Differences in QoL between AT III
and placebo were estimated for each attribute. Two-sample
Wilcoxon statistical tests were used to determine whether the
changes were different between treatment groups.
Differences among patient subgroups
Similarly, Wilcoxon tests were used to identify whether
changes in the QoL scores differed for subgroups between
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Table 2
Visual analog scale: subjective assessment of physical
performance and dependency
Domain Definition
Mobility How would you rate this patient’s mobility 
today?
Physical activity How would you rate this patient’s 
physical activity today?
Communications/speech How would you rate this patient’s 
communication/speech today?
Alertness How would you rate this patient’s level of 
alertness today?
Energy How would you rate this patient’s energy 
level today?
Overall quality of life How would you rate this patient’s overall 
quality of life today?baseline and 90 days. This analysis was done on the all-sur-
vivors population.
Changes in quality of life between baseline and 28, 56, and
90 days
For the all-survivors and in-hospital survivors subgroups, com-
parative differences in changes between baseline and 28, 56,
and 90 days were estimated. For each attribute, the differ-
ence in mean change between treatment groups is pre-
sented, together with two-sided 95% confidence intervals, so
that the differences between placebo and AT III over time are
clearly shown.
Statistical considerations
Nominal  P values should be regarded as descriptive
because no formal null hypothesis was prespecified and no
type I error probability can be indicated. No adjustment of P
values for multiple testing or multiple confidence intervals
was made. P values less than or equal to 0.05 were consid-
ered statistically significant. P values above 0.05 but less
than or equal to 0.10 were considered indicative of a trend.
Confidence intervals for the difference between mean
changes were constructed assuming a normal distribution of
changes from baseline.
Results
Patient characteristics
Table 3 shows baseline patient demographic data and
heparin administration for the 2314 patients who entered the
KyberSept trial. The all-survivors group using the last obser-
vation carried forward analysis totaled 897 patients, whereas
the in-hospital group totaled 118. The patients included in
this study population were from a broad mixture of countries.
The mean ± SD age of the overall population was
58 ± 17 years in the placebo group and 57 ± 17 years in the
AT III group. Mean age was lower (53 ± 17 years) in the all-
survivors population. A clear majority of patients were men
(61.5% men versus 38.5% women). In the three populations
(overall, all 90 day survivors, and 90 day in-hospital survivors),
the sex distribution for the AT III groups was similar. There
was a shift toward the lower risk strata of SAPS II score from
the overall population to the all-survivors population, whereas
the risks in the in-hospital population were slightly higher than
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Table 3
Characteristics of patients in the KyberSept trial
Overall population* All 90-day survivors 90-day in-hospital 
Parameter Placebo (n = 1157) AT III (n = 1157) Placebo (n = 437) AT III (n = 460) Placebo (n = 55) AT III (n = 63)
Age (years;  58 ± 17 (18–96) 57 ± 17 (18–93) 53 ± 17 (18–96) 53 ± 17 (18–88) 57 ± 15 (22–81) 56 ± 14 (21–79)
mean ± SD [range])
Sex (%)
M a l e 6 16 26 26 46 76 5
Female 39 38 38 36 33 35
Country (%)
USA 15 15 14 15 6 6
Czech Republic 11 11 12 11 18 10
South Africa 11 11 9 8 2 5
UK 8 8 9 9 13 13
Denmark 7 7 6 7 6 11
Germany 6 6 6 5 4 8
Other (13 countries) 40 40 43 46 53 48
SAPS II risk group (%)
Moderate risk (<30%) 27 29 43 40 24 24
High risk (30–60%) 45 42 40 43 36 41
Very high risk (>60%) 28 29 17 18 40 35
Admitting diagnosis (%)†
Respiratory system 34 35 33 34 33 24
Digestive system 28 27 29 27 38 40
Genitourinary system 8 6 11 8 4 2
Injury 6 7 5 7 0 10
Other 24 24 22 25 26 25
Concomitant heparin (%)
No 30 30 29 32 13 30
Yes 70 70 71 68 87 70
*All 2314 patients evaluable for efficacy in KyberSept study. †According to the International Classification of Diseases (9th edition). Percentages
may not add to 100 because of rounding. AT, antithrombin; SAPS, Simplified Acute Physiology Score.those in the overall population. In the all-survivors group respi-
ratory disorders were the most common diagnostic admitting
category, whereas digestive causes of sepsis were the most
common among the in-hospital group.
Among all patients enrolled in the trial, 70% received heparin
concomitantly. Among the all-survivors, placebo and AT III dif-
fered by 3% with respect to concomitant heparin administra-
tion. In this population 71% of placebo patients were
administered heparin concomitantly; 68% of those adminis-
tered AT III received heparin. Among the in-hospital survivors
at 90 days, 87% in the placebo group received heparin as
compared with 70% of those receiving AT III. Comparing AT
III groups across populations, the use of concomitant heparin
was nearly the same.
Changes in 90-day quality of life
Table 4 shows data for the six attributes of the visual analog
scale and the Karnofsky scale (objective physical perfor-
mance and dependency) measured from baseline to 90 days.
Assessment of the changes among the all-survivors, based
on two-sided, two-sample Wilcoxon tests, suggests advan-
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Table 4
Mean changes between baseline and 90 days for the attributes of survivors in the KyberSept trial: patients in hospital at 90 days
and all-survivors
In-hospital at day 90 All survivors*
Attribute Placebo (mean ± SD) AT III (mean ± SD) P† Placebo (mean ± SD) AT III (mean ± SD) P†
Mobility (%) 33 ± 26 38 ± 28 >0.1 49 ± 24 51 ± 24 >0.1
Physical activity (%) 33 ± 27 39 ± 26 >0.1 48 ± 23 50 ± 23 >0.1
Communication/speech (%) 42 ± 42 61 ± 35 0.01 52 ± 34 57 ± 32 0.03
Level of alertness (%) 41 ± 39 59 ± 33 0.02 51 ± 32 56 ± 31 0.02
Energy level (%) 34 ± 27 43 ± 26 0.09 47 ± 23 51 ± 22 0.02
Overall QoL (%) 35 ± 28 44 ± 27 >0.1 51 ± 23 53 ± 23 >0.1
Karnofsky scale (%) 22 ± 19 31 ± 19 0.03 45 ± 19 47 ± 19 >0.1
Scores range from 0 to 100, and changes may range from –100 to +100. Higher scores represent better quality of life (QoL) and increases (i.e.
positive changes) represent improvement. *90-day values calculated by last observation carried forward analysis (see text). †Nominal P value for
two-sided, two-sample Wilcoxon test for differences between changes from baseline to 90-day QoL. AT, antithrombin.
Table 5
Mean increase in scores from baseline to 90 day in the KyberSept Trial by subgroups: all-survivors
Physical Communications/ Level  of 
Mobility activity speech alertness Energy level Overall QoL Karnofsky
Parameter Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III Placebo AT III
SAPS II risk
Moderate 49±23 51±24 48±22 50±23 43±35 48±33 43±34 47±33 47±22 49±22 50±23 50±21 49±18 49±18
High 51±24 52±23 50±22 51±22 58±31 61±30 56±28 60±29 48±23 51±22† 53±22 54±23 44±19 46±19
Very high 47±26 52±26 44±25 50±25 59±35 66±29 59±33 67±28† 46±23 51±24 50±25 55±25 41±21 43±19
Admitting diagnosis
Respiratory 50±25 54±23† 48±23 52±23 51±35 59±33 52±32 58±32† 46±23 51±22† 52±24 55±22 46±19 49±18
Digestive 50±23 52±24 49±23 50±23 55±35 60±31 54±33 59±31 46±24 49±22† 52±23 51±24 45±19 46±19
Genitourinary 46±21 43±26 46±20 43±25 40±36 40±34 40±34 37±34 49±19 44±22 48±21 44±25 47±20 45±18
Injury 51±24 47±27 52±22 48±26 58±26 55±29 55±27 59±29 49±21 52±26† 53±18 53±24 67±21 70±19
Other 48±25 51±24 48±23 51±23 53±33 56±31 52±30 56±31 48±23 53±22 51±24 54±21 69±21 68±18
Concomitant heparin
No 44±22 48±24† 43±21 48±22* 42±36 51±31† 42±33 49±31 43±22 49±22† 47±22 51±23 43±19 43±19
Yes 51±24 53±24 50±23 52±24 55±33 60±32† 54±31 59±31* 48±23 52±22† 52±23 54±23 46±19 46±19
Values are expressed as mean ± SD. *P < 0.05 versus placebo; †P < 0.1 versus placebo. Mean scores represent changes between the 90-day and
the baseline values for all-survivors (those in hospital 90 days from study enrollment, or closest time point to 90 days [last observation carried
forward analysis; see text]). All mean scores increased (higher scores indicate better quality of life [QoL]). AT, antithrombin.tages for the AT III group as compared with the placebo
group in three of the attributes; namely, patient communica-
tion and speech, level of alertness, and energy level. In the in-
hospital population, the differences indicated that
communication and speech, level of alertness, and the
Karnofsky scale were all more improved for the AT III group
than for placebo.
In neither population was the change in patient overall QoL
judged to be statistically different. In the in-hospital group, a
trend toward greater patient energy levels in the AT III group
was found (P < 0.10).
Differences across patient subgroups
As shown in Table 5, although there were generally greater
increases in attribute scores in the SAPS II risk for AT III in
the all-survivors, none of the differences were statistically sig-
nificant. There were also no significant differences between
placebo and AT III according to the diagnostic subgroups on
hospital admission, although a few ‘trends’ favoring AT III
(notably the ‘energy level’ attribute of QoL) were found. In the
heparin subgroups, there was an advantage in some attrib-
utes for AT III. Compared with placebo, physical activity was
improved significantly more in the AT III subgroup than in the
placebo subgroup not receiving heparin. There was also a
trend toward greater improvement in three other attributes in
the no concomitant heparin subgroup, namely patient mobil-
ity, communication and speech, and patient energy level.
Excluding the Karnofsky scores that were unchanged, mean
nominal changes in the AT III QoL attributes of the no con-
comitant heparin group ranged from +4 to +9, whereas those
receiving concomitant heparin experienced nominal increases
in scores ranging from +2 to +5.
Changes in quality of life between baseline and 28, 56,
and 90 days
Figs 1 and 2 show the differences in mean changes in scores
between baseline and later periods for the seven attributes
measured in the AT III group as compared with placebo.
Fig. 1 shows results for the all-survivors population, whereas
Fig. 2 shows findings in the in-hospital population. Consider-
ing point estimates of differences between mean changes at
each time point, for all attributes and in both populations AT
III patients were more improved than placebo patients. Confi-
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Figure 1
Difference in changes between treatment groups in quality of life
attributes over time: all-survivors.
Figure 2
Difference in changes between treatment groups in quality of life
attributes over time: in-hospital survivors.dence intervals fully occupying the ‘AT III better’ side indicate
statistically significant improvements in the AT III group. In the
all-survivors population, comparative improvements tended to
increase over time in the AT III group as compared with the
placebo group. An exception was the Karnofsky index, for
which the difference between treatment groups remained
approximately constant over time. For the in-hospital popula-
tion, the advantage in the AT III group increased over time for
the communication/speech and the level of alertness attrib-
utes, whereas the difference between treatment groups
remained approximately constant for the other attributes. In
the all-survivors, the greatest comparative advantages for the
AT III group were found in communication/speech, alertness,
and energy level.
Discussion
The present study represents the first attempt to evaluate
patient QoL over a relatively long period in a large, random-
ized, placebo-controlled sepsis trial. The results of the study
indicate that, over a 90-day period, survivors of severe sepsis
receiving AT III experienced substantial and statistically signif-
icant improvements as compared with placebo in several
attributes of QoL. These results held for both all-survivors and
in-hospital survivors populations. The comparative advantage
in QoL for AT III was also maintained from 28 to 56, and
90 days. After 90 days, the study also found an advantage
with AT III for some attributes in patients who did not receive
heparin concomitantly.
The improvements identified in the study should be inter-
preted in terms of statistical and clinical significance. Clinical
significance deals with the applied value of the change in
everyday life. Unfortunately, as with most other QoL instru-
ments, there is not yet a clear standard for ‘minimal clinically
important differences’. However, improvements by approxi-
mately 20% in the in-hospital group of AT III sepsis patients
after 90 days in communication/speech and level of alertness
probably represent meaningful improvements in many
patients.
Another limitation of the present study is the fact that investi-
gators were proxy respondents, rather than patients respond-
ing themselves. Like many studies of QoL in critical care
settings, physicians were assumed to be sufficiently close to
patients to provide valid and reliable data. Although this was
not substantiated empirically, there is usually moderate agree-
ment between patients and proxies, although lower levels of
agreement have been found in psychosocial functioning
[17,18].
Conclusion
Combined with previous findings in 90-day mortality for those
without concomitant administration of heparin, this multi-
national study demonstrates that AT III is associated with
meaningful improvements in health for many sepsis patients
over an extended 3-month follow-up period. In this subgroup,
the clinical improvements over a long time period in patients
in the AT III group were complemented by improvements in
QoL in many patients, particularly in terms of social and psy-
chologic functioning. Although no significant reduction in 90-
day mortality was found for the overall population, a nominal
advantage in mortality for the AT III group combined with a
generally improved QoL profile in the survivors of this group
suggests a possible long-term benefit from AT III. Future
studies of critically ill patients with severe sepsis or other
conditions should include long-term follow up of patients
throughout hospitalization and after hospital discharge. In
sepsis, long-term follow up appears to provide more mean-
ingful outcome data for patients, families, and society than do
standard 28-day, all-cause mortality statistics.
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